CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Animals
CD8-Positive T-Lymphocytes
/ immunology
Cells, Cultured
Disease Models, Animal
Female
HLA-A2 Antigen
/ immunology
Healthy Volunteers
Humans
Immunoglobulin Fc Fragments
/ immunology
Interleukin-2
/ immunology
Leukocytes, Mononuclear
Mice
Mice, Inbred C57BL
Mice, Transgenic
Neoplasms
/ immunology
Papillomavirus E7 Proteins
/ immunology
Tumor Necrosis Factor Receptor Superfamily, Member 7
/ immunology
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
14
10
2019
revised:
05
12
2019
accepted:
13
01
2020
pubmed:
23
1
2020
medline:
28
1
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
To assess the potential for CUE-101, a novel therapeutic fusion protein, to selectively activate and expand HPV16 E7 CUE-101 is an Fc fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain. Human E7-specific T cells and human peripheral blood mononuclear cells (PBMC) were tested to demonstrate cellular activity and specificity of CUE-101, whereas CUE-101 demonstrates selective binding, activation, and expansion of HPV16 E7 Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E7
Identifiants
pubmed: 31964784
pii: 1078-0432.CCR-19-3354
doi: 10.1158/1078-0432.CCR-19-3354
doi:
Substances chimiques
HLA-A2 Antigen
0
Immunoglobulin Fc Fragments
0
Interleukin-2
0
Papillomavirus E7 Proteins
0
Tumor Necrosis Factor Receptor Superfamily, Member 7
0
oncogene protein E7, Human papillomavirus type 16
0
Banques de données
ClinicalTrials.gov
['NCT03978689']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1953-1964Informations de copyright
©2020 American Association for Cancer Research.